CINXE.COM

<!DOCTYPE html> <html lang="en"> <head> <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" /> <meta charset="utf-8" /> <meta name="viewport" content="width=device-width, initial-scale=1"/> <link rel="shortcut icon" href="/ResourcePackages/ISPOR/assets/dist/images/favicon2018.ico" /> <title> ISPOR RWE Summit 2023 - Program </title> <link href="https://fonts.googleapis.com/css?family=Open+Sans:400,600,600i,700|Oswald:200,400,500,700" rel="stylesheet" type="text/css" /><link href="/ResourcePackages/ISPOR/assets/dist/css/site.css?v=2024-07-25-10:06" rel="stylesheet" type="text/css" /><link href="/ResourcePackages/ISPOR/modules/confex-sessions-v2/dist/assets/index.css?v=2023-09-07-10:08&package=ISPOR" rel="stylesheet" type="text/css" />  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-PDHP8D9');</script>   <script data-ad-client="ca-pub-5906864804318753" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>  <meta property="og:title" content="ISPOR RWE Summit 2023 - Program" /><meta property="og:url" content="https://www.ispor.org/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program/program" /><meta property="og:type" content="website" /><meta property="og:site_name" content="ISPOR.org" /><style type="text/css" media="all">.banner--conference-interior .home-bkg h2 { font-size: 1.5rem; } .banner--conference-interior .home-bkg > .container > div { flex-direction: column; } @media screen and (min-width: 769px) { .banner--conference-interior .home-bkg h2 { font-size: 3rem; } .banner--conference-interior .home-bkg > .container > div { flex-direction: row; justify-content: space-between; } }</style><style type="text/css" media="all">.banner--conference{ background-color: #94cfee;} </style><style type="text/css" media="all">.container .col-md-12 { padding-left: 0 !important; padding-right: 0 !important; </style><meta name="Generator" content="Sitefinity 14.3.8029.0 DX" /><link rel="canonical" href="https://www.ispor.org/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program/program" /><meta name="published" content="2020-01-01T08:00:00Z" /><meta name="PublicationDate" content="2020-01-01T08:00:00Z" /></head> <body>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PDHP8D9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>   <script src="/ScriptResource.axd?d=okuX3IVIBwfJlfEQK32K3pJq8rdlrgjKVdts-gGrv2kG4k9gDy9nnJ4QmOS7qIpGYwnvZImFv67AkYflXzQzL1XXdLk6cE73E-Y02Il5u7GPSSCFweLiF_ikM4O8JqW-ZWEOMvFmi82K_O19dC4sV-ag9d7IYTbiqkpJFlXn7WI5U3aQoGeg-B_XKQYTx61C0&t=ffffffff8f08a73f" type="text/javascript"></script><script src="/ScriptResource.axd?d=ePnjFy9PuY6CB3GWMX-b_9XYTLC4_i5QxrubVqilgXGAUhjnbMwBd6UOk7HmbZ1_bK3lyqokLQF6SmYeGCGgO8eyTFVibbp9dcJSu3EkOJ4bB4TWTlyahzz-napeU8x8qAz8Zm5gT3Q4v_k4REYoD686ulSV-B3sJk3YTxIfBOKjc3OhcMftcLOWLQHcLadE0&t=ffffffff8f08a73f" type="text/javascript"></script><script src="/Frontend-Assembly/Telerik.Sitefinity.Frontend/Mvc/Scripts/Bootstrap/js/bootstrap.min.js?package=ISPOR&v=MTQuMy44MDI5LjA%3d" type="text/javascript"></script> <div class="conference-header"> <header class="section__header"> <div id="Header_TBB0D3FF1010_Col00" class="sf_colsIn container" data-sf-element="Container" data-placeholder-label="Container"><div class="flex-apart interior__header" data-sf-element="Row"> <div id="Header_TBB0D3FF1011_Col00" class="sf_colsIn logo" data-sf-element="Logo" data-placeholder-label="Logo"> <div > <div class="sfContentBlock sf-Long-text" ><a href="/home"><svg viewBox="0 0 150 48" width="213" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><rect height="124" id="b" rx="10" width="1440" x="-953" y="-10421"></rect><filter filterUnits="objectBoundingBox" height="100.1%" id="a" width="100.5%" x="-.2%" y="0%"><feoffset dy="7" in="SourceAlpha" result="shadowOffsetOuter1"></feoffset><fecomposite in="shadowOffsetOuter1" in2="SourceAlpha" operator="out" result="shadowOffsetOuter1"></fecomposite><fecolormatrix in="shadowOffsetOuter1" values="0 0 0 0 0.882352941 0 0 0 0 0.909803922 0 0 0 0 0.929411765 0 0 0 1 0"></fecolormatrix></filter> </defs> <g fill="none" fill-rule="evenodd"><use fill="#000" filter="url(#a)" xlink:href="#b"></use><use fill="#FFF" xlink:href="#b"></use><rect height="12416" rx="10" stroke="#E1E8ED" width="1439" x="-952.5" y="-10420.5"></rect><g><g fill-rule="nonzero"><g fill="#716658"><path d="M45.094 31.254h-2.977V2.263h2.977zM63.893 6.913c-.642-.861-1.46-1.55-2.452-2.124-.992-.517-2.218-.804-3.62-.804-.7 0-1.46.115-2.218.345a7.44 7.44 0 0 0-2.043.976c-.584.459-1.11 1.033-1.46 1.722a5.265 5.265 0 0 0-.584 2.41c0 .92.175 1.723.526 2.297.35.574.817 1.09 1.46 1.55.583.402 1.284.746 2.043 1.034a29.12 29.12 0 0 0 2.393.803c1.051.345 2.044.69 3.094 1.091 1.051.402 1.985.861 2.803 1.493.817.631 1.518 1.377 2.043 2.353.525.919.817 2.124.817 3.56 0 1.435-.292 2.698-.817 3.731-.584 1.033-1.284 1.894-2.16 2.583a8.138 8.138 0 0 1-3.094 1.493 12.327 12.327 0 0 1-3.503.517c-.876 0-1.752-.115-2.686-.287a13.317 13.317 0 0 1-2.569-.804 9.237 9.237 0 0 1-2.276-1.378c-.701-.574-1.285-1.148-1.81-1.894l2.569-1.895c.642 1.034 1.517 1.895 2.685 2.584 1.168.688 2.51 1.033 4.087 1.033.759 0 1.518-.115 2.277-.345a6.115 6.115 0 0 0 2.101-1.09 4.984 4.984 0 0 0 1.518-1.78c.409-.689.584-1.493.584-2.411 0-1.033-.175-1.837-.584-2.526-.408-.689-.934-1.206-1.576-1.665-.642-.46-1.46-.804-2.277-1.148a75.78 75.78 0 0 1-2.685-.918 24.15 24.15 0 0 1-2.861-1.034c-.934-.402-1.81-.86-2.569-1.492a7.078 7.078 0 0 1-1.81-2.297c-.467-.918-.7-2.009-.7-3.33 0-1.377.292-2.583.875-3.616.584-1.033 1.285-1.837 2.219-2.526.934-.631 1.927-1.148 3.036-1.435 1.109-.287 2.218-.46 3.27-.46 1.984 0 3.736.345 5.137 1.034 1.4.689 2.51 1.55 3.21 2.468l-2.393 2.182zM69.848 2.263h8.349c1.517 0 2.86.172 4.086.46a8.794 8.794 0 0 1 3.153 1.434 6.33 6.33 0 0 1 2.043 2.412c.467.975.7 2.124.7 3.444 0 1.32-.233 2.468-.7 3.444a6.33 6.33 0 0 1-2.043 2.412 8.794 8.794 0 0 1-3.153 1.435c-1.226.344-2.627.516-4.086.516h-5.255v13.491h-2.977V2.263h-.117zm2.977 13.031h5.08c2.335 0 4.145-.459 5.37-1.377 1.227-.919 1.81-2.24 1.81-3.961 0-1.78-.642-3.1-1.868-3.962-1.284-.86-3.035-1.263-5.312-1.263h-5.08v10.563zM119.88 16.787c0 2.239-.408 4.248-1.167 6.085-.759 1.837-1.868 3.445-3.21 4.822a14.058 14.058 0 0 1-4.905 3.158 16.61 16.61 0 0 1-6.13 1.148 16.61 16.61 0 0 1-6.13-1.148c-1.868-.746-3.503-1.837-4.904-3.158-1.401-1.377-2.452-2.985-3.21-4.822-.76-1.837-1.169-3.903-1.169-6.085 0-2.239.41-4.248 1.168-6.085.76-1.837 1.868-3.445 3.211-4.822a14.058 14.058 0 0 1 4.904-3.158c1.868-.746 3.912-1.148 6.13-1.148 2.219 0 4.204.402 6.13 1.148 1.868.747 3.503 1.837 4.904 3.158 1.401 1.377 2.452 2.985 3.211 4.822.76 1.837 1.168 3.846 1.168 6.085zm-3.152 0c0-1.665-.292-3.272-.817-4.822-.584-1.55-1.343-2.87-2.394-4.019-1.05-1.148-2.335-2.066-3.853-2.755-1.518-.69-3.21-1.034-5.079-1.034-1.868 0-3.62.345-5.08 1.034-1.517.689-2.802 1.607-3.852 2.755a11.736 11.736 0 0 0-2.394 4.019c-.584 1.55-.817 3.157-.817 4.822s.292 3.272.817 4.822c.584 1.55 1.343 2.87 2.394 4.019 1.05 1.148 2.335 2.066 3.853 2.755 1.518.69 3.21 1.034 5.079 1.034 1.868 0 3.62-.345 5.08-1.034 1.517-.689 2.801-1.607 3.852-2.755a11.22 11.22 0 0 0 2.394-4.019c.525-1.55.817-3.157.817-4.822zM125.836 31.254h-2.978V2.263h8.64c1.46 0 2.803.115 4.03.402 1.225.287 2.276.689 3.21 1.32a7.046 7.046 0 0 1 2.102 2.411c.525.976.759 2.182.759 3.617 0 1.09-.175 2.01-.584 2.928a8.971 8.971 0 0 1-1.576 2.296c-.642.632-1.46 1.148-2.394 1.55-.934.402-1.927.632-2.977.746l8.64 13.836h-3.678l-8.173-13.549h-5.021v13.434zm0-16.074h5.196c2.393 0 4.262-.402 5.604-1.263 1.285-.861 1.985-2.124 1.985-3.847 0-.976-.175-1.78-.525-2.41a4.474 4.474 0 0 0-1.518-1.608c-.642-.402-1.401-.689-2.335-.919a16.502 16.502 0 0 0-3.036-.287h-5.313V15.18h-.058z"></path></g> <circle cx="16.67" cy="10.311" fill="#4FA0CA" r="2.39" transform="rotate(-45 16.67 10.311)"></circle><circle cx="23.097" cy="10.304" fill="#999" r="2.39" transform="rotate(-45 23.097 10.304)"></circle><circle cx="29.523" cy="10.297" fill="#999" r="2.39" transform="rotate(-45 29.523 10.297)"></circle><circle cx="3.858" cy="10.285" fill="#999" r="2.39" transform="rotate(-45 3.858 10.285)"></circle><circle cx="10.244" cy="10.318" fill="#999" r="2.39" transform="rotate(-45 10.244 10.318)"></circle><circle cx="16.69" cy="3.931" fill="#999" r="2.39" transform="rotate(-45 16.69 3.93)"></circle><circle cx="23.117" cy="3.924" fill="#999" r="2.39" transform="rotate(-45 23.117 3.924)"></circle><circle cx="10.264" cy="3.938" fill="#999" r="2.39" transform="rotate(-45 10.264 3.938)"></circle><circle cx="23.117" cy="16.725" fill="#999" r="2.39" transform="rotate(-45 23.117 16.725)"></circle><circle cx="29.543" cy="16.718" fill="#4FA0CA" r="2.39" transform="rotate(-45 29.543 16.718)"></circle><circle cx="3.878" cy="16.706" fill="#999" r="2.39" transform="rotate(-45 3.878 16.706)"></circle><circle cx="10.264" cy="16.739" fill="#999" r="2.39" transform="rotate(-45 10.264 16.74)"></circle><circle cx="16.67" cy="23.113" fill="#999" r="2.39" transform="rotate(-45 16.67 23.113)"></circle><circle cx="23.096" cy="23.106" fill="#999" r="2.39" transform="rotate(-45 23.096 23.106)"></circle><circle cx="29.523" cy="23.099" fill="#999" r="2.39" transform="rotate(-45 29.523 23.099)"></circle><circle cx="3.858" cy="23.087" fill="#999" r="2.39" transform="rotate(-45 3.858 23.087)"></circle><circle cx="10.244" cy="23.12" fill="#4FA0CA" r="2.39" transform="rotate(-45 10.244 23.12)"></circle><circle cx="16.69" cy="29.534" fill="#999" r="2.39" transform="rotate(-45 16.69 29.534)"></circle><circle cx="23.117" cy="29.527" fill="#999" r="2.39" transform="rotate(-45 23.117 29.527)"></circle><circle cx="10.264" cy="29.541" fill="#999" r="2.39" transform="rotate(-45 10.264 29.541)"></circle><g fill="#716658"><path d="M44.206 42.267c-.058.2-.058.266-.116.466H42c.058-.2.058-.266.116-.466h.755l.754-4.2h-.754c.058-.2.058-.267.116-.467h1.973c-.058.2-.058.267-.116.467h-.754l-.755 4.2h.87zM45.309 39.2c.522-.133.87.133.754.6.348-.467.755-.667 1.22-.667.522 0 .754.334.754.8.29-.533.812-.8 1.335-.8.812 0 .929.734.754 1.534l-.232 1.2c-.058.4-.116.533.349.466l-.059.4c-.696.134-.928-.066-.754-.8l.232-1.266c.116-.6 0-1.067-.522-1.067-.523 0-.93.467-1.045 1.067l-.406 2.066h-.523l.406-2.066c.117-.6 0-1.067-.522-1.067s-.987.4-1.103 1.067l-.406 2.066h-.523l.465-2.466c.116-.534.116-.734-.29-.667l.116-.4zM50.707 44.6l.813-4.533c.058-.267.116-.467-.29-.467l.057-.4c.523-.067.813.067.697.6v.133c.29-.466.696-.733 1.16-.733.988-.067 1.278.867 1.22 1.8-.116 1.067-.813 2-1.742 2-.464 0-.812-.2-.986-.733l-.465 2.466h-.464V44.6zm1.857-2.267c.755 0 1.22-.8 1.335-1.533.058-.733-.174-1.2-.812-1.2-.755 0-1.277.867-1.277 1.733 0 .6.232 1 .754 1zM57.15 39.067c.29 0 .522.066.697.266l-.233.467c-.174-.133-.348-.267-.638-.267-.465 0-.929.4-1.045.934l-.406 2.2h-.523c.232-1.334.232-1.4.523-2.734.058-.333.116-.533-.29-.466l.058-.4c.522-.067.812-.067.754.533.29-.4.639-.533 1.103-.533zM59.24 42.8c-.697 0-1.335-.467-1.335-1.467 0-1.466 1.102-2.2 2.031-2.2.697 0 1.335.534 1.335 1.467 0 1.467-.928 2.2-2.031 2.2zm.058-.467c.696 0 1.45-.466 1.45-1.666.059-.667-.405-1.067-.928-1.067-.638 0-1.451.6-1.451 1.667.058.733.464 1.066.929 1.066zM64.522 39.2h.522c.174 1.4.116 3.6-1.8 3.6-.812 0-1.276-.6-1.102-1.533l.174-.934c.058-.466.232-.8-.232-.8l.058-.4c.58-.133.929.067.755.8l-.233 1.334c-.116.6.058 1.066.697 1.066 1.335 0 1.335-2.2 1.16-3.133zM66.205 42.8h-.522l.638-3.533h.523l-.639 3.533zm.697-5.133c.116 0 .29.066.29.266 0 .267-.232.467-.406.467-.116 0-.233-.067-.233-.267-.058-.333.175-.466.349-.466zM67.714 39.2c.523-.133.813.067.755.6.29-.467.755-.667 1.219-.667.813 0 1.103.667.987 1.534L70.443 42c-.059.333-.059.467.29.4l-.058.4c-.58.133-.871 0-.755-.8l.232-1.333c.116-.667-.174-1.067-.696-1.067-.523 0-.987.4-1.103 1.067l-.406 2.066h-.523l.465-2.533c.116-.533.174-.733-.29-.667l.115-.333zM71.313 43.867c.755.533 2.09.6 2.38-.934l.174-.866c-.29.533-.696.733-1.219.733-.87 0-1.16-.867-1.103-1.667.175-1.333 1.045-2.066 2.09-2.066.406 0 .813.133 1.161.333l-.639 3.467c-.348 1.733-1.683 2.133-2.96 1.4l.116-.4zm2.903-4.067a1.44 1.44 0 0 0-.755-.2c-.755 0-1.393.533-1.451 1.467-.116.6.116 1.266.696 1.266.639 0 1.161-.733 1.277-1.4l.233-1.133zM77.64 42.8h-.522l.987-5.4h.522l-.464 2.333c.232-.333.754-.533 1.16-.533.93 0 1.103.867.93 1.733l-.175 1c-.058.334-.058.534.348.467l-.058.467c-.754.133-.87-.134-.754-.867l.174-1c.174-.867 0-1.267-.639-1.267-.522 0-.986.467-1.102 1.067l-.407 2zM83.735 42.6c-.406.2-.755.267-1.103.267-1.103 0-1.625-.8-1.335-2.067.29-1.067 1.045-1.6 1.916-1.667.638 0 1.277.334 1.103 1.2-.175.8-.871 1.067-1.394 1.067-.406 0-.87-.067-1.16-.333-.175.933.232 1.4.986 1.4.349 0 .755-.134 1.103-.334l-.116.467zm-.87-1.733c.348 0 .812-.134.928-.6.116-.467-.348-.667-.696-.667-.523 0-.987.333-1.22.933.175.267.64.334.987.334zM87.682 41.8c-.058.333-.116.533.29.533l-.058.467c-.522.067-.812-.067-.696-.6v-.133c-.29.533-.813.8-1.277.8-.929 0-1.277-.867-1.045-1.867.232-1.2 1.045-1.8 2.09-1.8.406 0 .812.133 1.16.333l-.464 2.267zm-.116-2a1.599 1.599 0 0 0-.755-.2c-.696 0-1.277.533-1.45 1.4-.117.733.057 1.267.696 1.267.638 0 1.16-.534 1.277-1.334l.232-1.133zM90.236 37.333l-.754 4.134c-.116.666-.058.933.638.866l-.058.467c-.987.2-1.277-.2-1.045-1.333l.755-4.134h.464zM92.036 39.2h1.16l-.057.4h-1.161l-.349 1.733c-.232 1.067.29 1.134 1.103.867v.467c-1.103.4-1.8.066-1.567-1.334l.348-1.733-.638-.067.058-.4h.696L91.861 38h.407l-.232 1.2zM93.893 42.8h-.522l.986-5.4h.523l-.464 2.333c.232-.333.754-.533 1.16-.533.93 0 1.103.867.93 1.733l-.175 1c-.058.334-.058.534.348.467l-.058.467c-.754.133-.87-.134-.754-.867l.174-1c.174-.867 0-1.267-.639-1.267-.522 0-.986.467-1.103 1.067l-.406 2zM100.278 40.267c-.058-.467-.464-.667-.812-.667-.58 0-1.277.533-1.452 1.4-.116.733.175 1.267.813 1.333.406 0 .87-.2 1.16-.733h.523c-.348.867-1.103 1.267-1.741 1.267-.813 0-1.393-.667-1.335-1.667.174-1.4 1.16-2.067 2.032-2.067.638 0 1.16.4 1.218 1.2h-.406v-.066zM104.167 41.8c-.058.333-.116.533.29.533l-.058.467c-.522.067-.812-.067-.696-.6v-.133c-.29.533-.813.8-1.277.8-.929 0-1.277-.867-1.045-1.867.232-1.2 1.045-1.8 2.09-1.8.406 0 .812.133 1.16.333l-.464 2.267zm-.116-2a1.599 1.599 0 0 0-.754-.2c-.697 0-1.277.533-1.452 1.4-.116.733.058 1.267.697 1.267.638 0 1.16-.534 1.277-1.334l.232-1.133zM107.36 39.067c.29 0 .522.066.696.266l-.232.467c-.174-.133-.348-.267-.638-.267-.465 0-.93.4-1.045.934l-.407 2.2h-.464c.232-1.334.232-1.4.523-2.734.058-.333.116-.533-.29-.466l.057-.4c.523-.067.813-.067.755.533.29-.4.638-.533 1.045-.533zM110.726 42.6c-.406.2-.754.267-1.102.267-1.103 0-1.626-.8-1.335-2.067.29-1.067 1.044-1.6 1.915-1.667.639 0 1.277.334 1.103 1.2-.174.8-.87 1.067-1.393 1.067-.407 0-.87-.067-1.161-.333-.174.933.232 1.4.987 1.4.348 0 .754-.134 1.103-.334l-.117.467zm-.87-1.733c.348 0 .812-.134.928-.6.117-.467-.348-.667-.696-.667-.522 0-.987.333-1.219.933.174.267.58.334.987.334zM117.344 37.333l-.813 4.467c-.058.333-.116.533.29.533l-.058.467c-.522.067-.754-.067-.696-.6v-.133c-.29.533-.755.8-1.277.8-.755 0-1.161-.667-1.161-1.467 0-1.133.696-2.333 1.8-2.333.464 0 .928.2.986.733l.464-2.467h.465zM116.24 40.6c0-.6-.232-1.067-.755-1.067-.812 0-1.219.8-1.335 1.534-.058.6.116 1.2.697 1.2.812 0 1.393-.734 1.393-1.667zM120.188 42.6c-.406.2-.755.267-1.103.267-1.103 0-1.625-.8-1.335-2.067.29-1.067 1.045-1.6 1.916-1.667.638 0 1.277.334 1.102 1.2-.174.8-.87 1.067-1.393 1.067-.406 0-.87-.067-1.16-.333-.175.933.232 1.4.986 1.4.348 0 .755-.134 1.103-.334l-.116.467zm-.87-1.733c.348 0 .812-.134.928-.6.116-.467-.348-.667-.697-.667-.522 0-.986.333-1.219.933.175.267.639.334.987.334zM124.077 40.267c-.058-.467-.464-.667-.813-.667-.58 0-1.277.533-1.45 1.4-.117.733.173 1.267.812 1.333.406 0 .87-.2 1.16-.733h.523c-.348.867-1.103 1.267-1.741 1.267-.813 0-1.393-.667-1.335-1.667.174-1.4 1.16-2.067 2.031-2.067.639 0 1.161.4 1.22 1.2h-.407v-.066zM125.528 42.8h-.522l.638-3.533h.523l-.639 3.533zm.697-5.133c.116 0 .29.066.29.266 0 .267-.232.467-.406.467-.116 0-.233-.067-.233-.267-.058-.333.175-.466.349-.466zM127.095 41.733c-.058.534.349.6.813.6.406 0 .929-.2.987-.6.058-.4-.232-.533-.755-.6-.522-.066-1.16-.266-1.16-.866 0-.8.754-1.2 1.509-1.2.638 0 1.218.333 1.102 1h-.464c.058-.4-.29-.534-.697-.534-.406 0-.928.2-.928.667 0 .267.29.4.754.467.639.066 1.277.266 1.103 1.133-.116.733-.812 1-1.567 1.067-.697 0-1.277-.267-1.161-1.067h.464v-.067zM130.636 42.8h-.522l.638-3.533h.523l-.639 3.533zm.697-5.133c.116 0 .29.066.29.266 0 .267-.232.467-.406.467-.116 0-.233-.067-.233-.267-.058-.333.117-.466.349-.466zM133.19 42.8c-.696 0-1.335-.467-1.335-1.467 0-1.466 1.103-2.2 2.032-2.2.696 0 1.335.534 1.335 1.467 0 1.467-.987 2.2-2.032 2.2zm.058-.467c.697 0 1.451-.466 1.451-1.666.058-.667-.406-1.067-.928-1.067-.639 0-1.451.6-1.451 1.667 0 .733.464 1.066.928 1.066zM136.15 39.2c.523-.133.813.067.755.6.29-.467.755-.667 1.22-.667.812 0 1.102.667.986 1.534L138.879 42c-.058.333-.058.467.29.4l-.058.4c-.58.133-.87 0-.755-.8l.233-1.333c.116-.667-.175-1.067-.697-1.067s-.987.4-1.103 1.067l-.406 2.066h-.523l.465-2.533c.116-.533.174-.733-.29-.667l.116-.333zM140.272 41.733c-.058.534.348.6.812.6.407 0 .93-.2.987-.6.058-.4-.232-.533-.754-.6-.523-.066-1.161-.266-1.161-.866 0-.8.754-1.2 1.509-1.2.638 0 1.219.333 1.103 1h-.465c.058-.4-.29-.534-.696-.534-.406 0-.929.2-.929.667 0 .267.29.4.755.467.638.066 1.277.266 1.103 1.133-.116.733-.813 1-1.568 1.067-.696 0-1.277-.267-1.16-1.067h.464v-.067z"></path></g> </g> </g> </g> </svg></a></div> </div> </div> <div id="top-utility" class="flex-center"> <div id="Header_TBB0D3FF1011_Col01" class="sf_colsIn" data-sf-element="Top Utility" data-placeholder-label="Top Utility"> <div > <div class="sfContentBlock sf-Long-text" ><a class="button back" href="https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-rwe-summit-2023">Back to ISPOR RWE Summit 2023 Home</a></div> </div> </div> <div class="js-element is-hidden mg-site-search"> <button type="button" class="search__close"> <span class="glyphicon glyphicon-remove"></span> </button> <input name="q" type="text" class="input search-input" placeholder="enter keyword"> </div> <button type="button" class="button toggle-search toggle-search--show"> <span class="glyphicon glyphicon-search is-size-4"> </span> </button> <button type="button" class="button toggle-search toggle-search--hide"> <span class="glyphicon glyphicon-search is-size-4"> </span> </button> <div id="Header_TBB0D3FF1011_Col02" class="sf_colsIn membership" data-sf-element="Membership" data-placeholder-label="Membership"> <div > <div class="sfContentBlock sf-Long-text" ></div> </div> </div> </div> </div> </div> </header> <section class="section__primary-nav"> <div> <nav class="navbar navbar-static-top navbar-default navbar-default--conference" role="navigation"> <div class="container"> <div class="navbar-header"> <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div> <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"> <ul class="nav navbar-nav"> <li class="dropdown"> <a href="/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program" target="_self">Program </a> <span data-toggle="dropdown" class="dropdown-toggle icon-plus"></span> <ul class="dropdown-menu"> <li class=""> <a href="/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program/program-committee" target="_self">Program Committee</a> </li> <li class="dropdown-submenu"> <a href="/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program/program" target="_self">Program </a> <span class="dropdown-toggle icon-plus"></span> <ul class="dropdown-menu"> <li class=""> <a href="/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program/program/session" target="_self">Session</a> </li> <li class=""> <a href="/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program/program/paper" target="_self">Paper</a> </li> </ul> </li> </ul> </li> </ul> </div> </div> </nav> </div> </section> </div>  <main class="section__main"> <div class="banner--conference banner--conference-interior img-bkg" data-sf-element="Row"> <div id="Main_T8B58AE33001_Col00" class="sf_colsIn" data-sf-element="Background" data-placeholder-label="Background"> <img src="/images/default-source/event-images/summit-2018/ispor_summit_blue.png?sfvrsn=dd14c9ae_0" title="large-circle" alt="large-circle" /> </div> <div id="Main_T8B58AE33001_Col01" class="sf_colsIn home-bkg" data-sf-element="Text" data-placeholder-label="Text"> <div class="container" > <div class="sfContentBlock sf-Long-text" ><div><h2><span class="text--white">ISPOR</span> Real-World Evidence Summit 2023</h2><h3>May 7, 2023</h3></div></div> </div> </div> </div><div class="row section" data-sf-element="Row"> <div id="Main_T8B58AE33005_Col00" class="sf_colsIn section container" data-sf-element="Column 1" data-placeholder-label="Column 1"><div class="row" data-sf-element="Row"> <div id="Main_T53118E99023_Col00" class="sf_colsIn col-md-12" data-sf-element="Column 1" data-placeholder-label="Column 1"><div> <ul class="sf-breadscrumb breadcrumb"> <li><a href="/">Home </a></li> <li><a href="/conferences-education">Events </a></li> <li><a href="/conferences-education/conferences/past-conferences">Past Conferences </a></li> <li><a href="/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023">ISPOR RWE Summit 2023 </a></li> <li><a href="/conferences-education/conferences/past-conferences/ispor-rwe-summit-2023/program">Program </a></li> <li class="active">Program</li> </ul> </div> <h1 class="interior-layout__title">Program</h1> <div class="row mt-8" data-sf-element="Row"> <div id="Main_C006_Col00" class="sf_colsIn col-md-8 pl-0" data-sf-element="Column 1" data-placeholder-label="Column 1"> </div> <div id="Main_C006_Col01" class="sf_colsIn col-md-4 pr-0 text-right" data-sf-element="Column 2" data-placeholder-label="Column 2"> </div> </div> <div class="row" data-sf-element="Row"> <div id="Main_C022_Col00" class="sf_colsIn col-md-12" data-sf-element="Column 1" data-placeholder-label="Column 1"> <div > <div class="sfContentBlock sf-Long-text" ></div> </div> </div> </div> <script> window.confexData = [{"title":"Registration Hours","subtitle":"","description":"","startTime":"12:00","startPeriod":"PM","endTime":"4:00","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"5d126092-4b1a-48e2-a395-8f0ec7247905","isPoster":false,"children":[],"childCount":0,"posterCategories":[],"programTypes":[{"id":"71fc216c-7a21-41c4-8fda-8fd52a67f29d","title":"General Meeting","urlName":"General-Meeting"}],"confexId":"Session16258","viewingMethods":[],"urlName":"rwes2023-16258","sponsorLogo":""},{"title":"Welcome","subtitle":"","description":"","startTime":"1:00","startPeriod":"PM","endTime":"1:10","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"1c594848-c6e0-4da3-915f-159120cef943","isPoster":false,"children":[],"childCount":0,"posterCategories":[],"programTypes":[{"id":"71fc216c-7a21-41c4-8fda-8fd52a67f29d","title":"General Meeting","urlName":"General-Meeting"}],"confexId":"Session15985","viewingMethods":[],"urlName":"rwes2023-15985","sponsorLogo":""},{"title":"Session 1","subtitle":"","description":"","startTime":"1:10","startPeriod":"PM","endTime":"2:10","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"a7645140-83c8-4e29-a006-51767d6713fa","isPoster":false,"children":[{"title":"From Data Quality to Qualities","id":"b6204f06-44b4-4c46-824d-f381de4c9816","description":"\r\n\t<div><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW114023864 BCX8\"><span class=\"NormalTextRun SCXW114023864 BCX8\">This session</span><span class=\"NormalTextRun SCXW114023864 BCX8\"> will examine how data quality is described and measured. </span><span class=\"NormalTextRun SCXW114023864 BCX8\">It will include</span><span class=\"NormalTextRun SCXW114023864 BCX8\"> a review</span><span class=\"NormalTextRun SCXW114023864 BCX8\"> and discussion</span><span class=\"NormalTextRun SCXW114023864 BCX8\"> of recent data quality frameworks,</span><span class=\"NormalTextRun SCXW114023864 BCX8\"> </span><span class=\"NormalTextRun SCXW114023864 BCX8\">development</span><span class=\"NormalTextRun SCXW114023864 BCX8\">s in validation</span><span class=\"NormalTextRun SCXW114023864 BCX8\">,</span><span class=\"NormalTextRun SCXW114023864 BCX8\"> and measurement of important aspects of quality. </span><span class=\"NormalTextRun SCXW114023864 BCX8\">It will include presentations from several experts followed by a brief panel discussion and Q&A.</span></span><span class=\"EOP SCXW114023864 BCX8\" data-ccp-props=\"{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}\"> </span></p>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW114023864 BCX8\"><span class=\"NormalTextRun SCXW114023864 BCX8\"></span></span></p>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW114023864 BCX8\"><span class=\"NormalTextRun SCXW114023864 BCX8\"></span></span></div>\r\n\r\n","sessionCode":"","prereq":"","children":[],"speakers":[{"type":"Moderator","people":[{"fullName":"Rachele Hendricks-Sturrup","lastName":"Hendricks-Sturrup","city":"Washington","state":"DC","country":"USA","bio":"","affiliations":"Duke-Margolis Center for Health Policy","credentials":"DHSc, MSc, MA","id":"a487cf86-cba1-4951-a29c-927ea9f8cd17","imageUrl":""}]},{"type":"Speaker","people":[{"fullName":"Andre Araujo","lastName":"Araujo","city":"Kennett Square","state":"PA","country":"USA","bio":"Andre B. Araujo, PhD is an epidemiologist and is the Head of Real-World Analytics (RWA) at GSK. The RWA team is composed of analysts and data scientists who provide design and analytics to support the generation of high-quality real-world evidence in support of the GSK portfolio. His external engagements include initiatives that focus on best practices in the application of research methods to real-world data in the context of non-interventional study designs.","affiliations":"GSK","credentials":"PhD","id":"10b149e9-d9e4-4dec-b2ea-f28041ec4e26","imageUrl":"https://ispor.confex.com/data/image/ispor/rwes2023/Person_272090_image_2907_0.jpg"},{"fullName":"Jaclyn L. Bosco","lastName":"Bosco","city":"Cambridge","state":"MA","country":"USA","bio":"Dr. Jaclyn Bosco is Vice President and Global Head of Epidemiology at IQVIA. She is responsible for driving real world evidence generation for regulators, clinicians, patients and payers using primary or passive data collection as well as existing data to support the safety and effectiveness of drugs, biologics, and medical devices from early clinical development through the post-approval phase. She sets industry best practices through external thought leadership as an invited speaker and panelist at international congresses and conferences on topics such as generating fit-for-purpose solutions using real-world evidence for regulatory decision-making. ","affiliations":"IQVIA","credentials":"PhD, MPH","id":"baf591e1-6635-4b1d-aa7b-fdee6eb6a361","imageUrl":"https://ispor.confex.com/data/image/ispor/rwes2023/Person_210831_image_2841_0.jpg"},{"fullName":"Sebastian Schneeweiss","lastName":"Schneeweiss","city":"Boston","state":"MA","country":"USA","bio":"","affiliations":"Harvard Medical School; Brigham and Women’s Hospital","credentials":"MD, ScD","id":"0578c6ae-06fe-4d8e-b5ff-c008588f032e","imageUrl":""}]}],"sponsorLogo":"","sponsorName":"","scTrack":"","scLevel":"Experienced","relatedPdfs":[{"url":"https://www.ispor.org/docs/default-source/rwes2023/session1slides.pdf?sfvrsn=bff75ea6_0","title":"Session_1_Slides"}],"confexId":"Session15963","viewingMethods":[],"searchableContent":"","sessionTypes":[{"id":"7e42f173-895f-448e-9964-5e5ca74dfc1b","title":"Issue Panel","urlName":"issue-panel"}],"topics":[{"id":"cd3b717f-305a-455d-b82a-8c3f75a7eb9f","title":"Real World Data & Information Systems","urlName":"real-world-data-information-systems"}],"urlName":"15963","parentUrlName":"rwes2023-3641","parentConfexId":"Symposium3641","shouldShowPdfs":true}],"childCount":1,"posterCategories":[],"programTypes":[{"id":"7c268d2c-e1f1-4b88-8a21-fb677a839ef1","title":"Issue Panel","urlName":"Issue-Panel"}],"confexId":"Symposium3641","viewingMethods":[{"id":"c6f373de-c02f-4f82-b4ce-3943fbc2e424","title":"Live","urlName":"live"}],"urlName":"rwes2023-3641","sponsorLogo":""},{"title":"Session 2","subtitle":"","description":"","startTime":"2:10","startPeriod":"PM","endTime":"3:10","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"2c93dd52-12d5-4495-8fa7-529928213897","isPoster":false,"children":[{"title":"Considering Data Qualities in Determining FFP - Can We Converge on an Approach?","id":"41ed8d5f-2c97-4388-a81b-5e7ed02e0c6e","description":"\r\n\t<div><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW1934789 BCX8\"><span class=\"NormalTextRun SCXW1934789 BCX8\">This session </span><span class=\"NormalTextRun SCXW1934789 BCX8\">will be </span><span class=\"NormalTextRun SCXW1934789 BCX8\">focused on the principles and realities of how fit-for-purpose decisions are made based on the needs of the study question and the qualities of the data</span><span class=\"NormalTextRun SCXW1934789 BCX8\">. </span><span class=\"NormalTextRun SCXW1934789 BCX8\">It will be primarily a panel discussion, considering questions such as “</span><span class=\"NormalTextRun SCXW1934789 BCX8\">How does the study question interact with data qualities to determine what’s fit-for-purpose”</span><span class=\"NormalTextRun SCXW1934789 BCX8\">?</span></span><span class=\"EOP SCXW1934789 BCX8\" data-ccp-props=\"{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}\"> </span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW1934789 BCX8\"><span class=\"NormalTextRun SCXW1934789 BCX8\"></span></span></div>\r\n\r\n","sessionCode":"","prereq":"","children":[],"speakers":[{"type":"Moderator","people":[{"fullName":"Marc Berger","lastName":"Berger","city":"New York","state":"NY","country":"USA","bio":"Marc L. Berger, MD, is a semi-retired, part-time consultant and scientific advisor. Until July 2017, he was Vice President, Real World Data and Analytics at Pfizer, Inc. Marc has held senior-level positions in industry including Executive Vice President and Senior Scientist at OptumInsight; Vice President, Global Health Outcomes at Eli Lilly and Company; and Vice President, Outcomes Research and Management at Merck & Co., Inc. He was a temporary employee of CMS from July-December 2022.\r\n\r\nMarc is an ISPOR Special Advisor for Real World Evidence and a member of the Duke-Margolis Center for Health Policy Real-World Evidence Collaborative. He has written or co-written more than 130 peer-reviewed articles, book chapters, and other publications on a range of topics including health services research, outcomes research, health economics, and health policy. He received the Donabedian Lifetime Achievement Award from ISPOR in 2019.","affiliations":"Marc L. Berger, LLC","credentials":"MD","id":"eefb0e22-b428-438b-bfbb-a866b366650b","imageUrl":"https://ispor.confex.com/data/image/ispor/intl2022/Person_229773_image_1064_0.JPG"}]},{"type":"Speaker","people":[{"fullName":"John Concato","lastName":"Concato","city":"Silver Spring","state":"MD","country":"USA","bio":"John Concato, MD, MS, MPH, is an Associate Director of the Office of Medical Policy, Center for Drug Evaluation and Research, FDA. His responsibilities related to real-world evidence (RWE) include developing internal Agency processes, interacting with stakeholders, coordinating demonstration projects and guidance development, and serving as Chair of the RWE Subcommittee. He joined FDA in 2019 after a career at Yale School of Medicine and the US Department of Veterans Affairs, where he was a clinician, educator, independent investigator, research center director, and Professor of Medicine.","affiliations":"Food and Drug Administration","credentials":"MD, MS, MPH","id":"e06a9d1c-dc19-4e9a-92dc-f53ab110777a","imageUrl":"https://ispor.confex.com/data/image/ispor/intl2022/Person_252652_image_1369_0.jpg"},{"fullName":"Gracy Crane","lastName":"Crane","city":"Welwyn","state":"HRT","country":"United Kingdom","bio":"Gracy Crane is a cancer biologist by training with a Master in Biomedical Research and a Ph.D. in Cancer Biology. She has also completed post-doctoral training fellowships at Oxford University (UK) and Massachusetts Institute of Technology (USA). \r\nShe has over 12 years of years of experience in the pharmaceutical industry, in varying roles including medical and scientific affairs, clinical development, health outcomes research and real world data. For the past 5 years, she has worked on leading the real world evidence strategy for molecules within the rare cancer space as part of the global Data Science team at Roche. Currently, she is the RWD policy lead within the Global Regulatory Policy team at Roche. She has authored many publications on this topic and has presented in many international conferences. \r\n\r\nGracy is also part of a number of external steering/working groups including the ISPOR RWD transparency Initiative (https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative), the CIOMs working group on RWD/E guidelines, and the Duke Margolis RWE Collaborative. She is also a co-author on the HARPER work: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.5507\r\n\r\nThis is her LinkedIn Profile: https://www.linkedin.com/in/gracy-crane-374ba120/\r\n","affiliations":"Roche Products Limited","credentials":"PhD","id":"3ef23477-8e44-41c8-a036-036aa604b097","imageUrl":""},{"fullName":"Laurie Lambert","lastName":"Lambert","city":"Ottawa","state":"ON","country":"Canada","bio":"Laurie Lambert completed a Master of Public Health in the epidemiology and biostatistics stream at the University of Western Australia. She then received a four-year Australian National Health and Medical Research Training scholarship to pursue her PhD. From 2004 to 2020, Laurie was the scientific coordinator of the Cardiovascular Evaluation Unit at INESSS where the focus was on evaluations of new technologies in the real-world context. In August, 2020 Laurie began a new chapter in her career as Lead of Real World Evidence at CADTH.","affiliations":"Canadian Agency for Drugs and Technologies in Health","credentials":"PhD","id":"51ee9dbe-70fa-4f92-b389-3348a3f7f79e","imageUrl":"https://ispor.confex.com/data/image/ispor/rwes2023/Person_272078_image_2453_0.jpg"},{"fullName":"Daniel Leaver Morales","lastName":"Leaver Morales","city":"Amsterdam","state":"","country":"Netherlands","bio":"","affiliations":"EMA","credentials":"","id":"e5229c97-7bd2-4c76-b555-dc21d217fb1e","imageUrl":""}]}],"sponsorLogo":"","sponsorName":"","scTrack":"","scLevel":"Experienced","relatedPdfs":[{"url":"https://www.ispor.org/docs/default-source/rwes2023/session2slides.pdf?sfvrsn=22d55729_0","title":"Session_2_Slides"}],"confexId":"Session15964","viewingMethods":[],"searchableContent":"","sessionTypes":[{"id":"7e42f173-895f-448e-9964-5e5ca74dfc1b","title":"Issue Panel","urlName":"issue-panel"}],"topics":[{"id":"cd3b717f-305a-455d-b82a-8c3f75a7eb9f","title":"Real World Data & Information Systems","urlName":"real-world-data-information-systems"}],"urlName":"15964","parentUrlName":"rwes2023-3642","parentConfexId":"Symposium3642","shouldShowPdfs":true}],"childCount":1,"posterCategories":[],"programTypes":[{"id":"7c268d2c-e1f1-4b88-8a21-fb677a839ef1","title":"Issue Panel","urlName":"Issue-Panel"}],"confexId":"Symposium3642","viewingMethods":[{"id":"c6f373de-c02f-4f82-b4ce-3943fbc2e424","title":"Live","urlName":"live"}],"urlName":"rwes2023-3642","sponsorLogo":""},{"title":"Break","subtitle":"","description":"","startTime":"3:10","startPeriod":"PM","endTime":"3:30","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"95672027-524b-4762-a6ea-90e6e84883c9","isPoster":false,"children":[],"childCount":0,"posterCategories":[],"programTypes":[{"id":"71fc216c-7a21-41c4-8fda-8fd52a67f29d","title":"General Meeting","urlName":"General-Meeting"}],"confexId":"Session15986","viewingMethods":[],"urlName":"rwes2023-15986","sponsorLogo":""},{"title":"Session 3","subtitle":"","description":"","startTime":"3:30","startPeriod":"PM","endTime":"4:30","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"8e1edf00-ef4b-4d02-8305-96fab841572c","isPoster":false,"children":[{"title":"Transparency in RWE: Ensuring Credibility and Confidence","id":"0e8abd4d-852e-4354-b63f-e14b3b168be4","description":"\r\n\t<div><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW235815615 BCX8\"><span class=\"NormalTextRun SCXW235815615 BCX8\">This session will cover areas of good conduct for RWE studies that help </span><span class=\"NormalTextRun SCXW235815615 BCX8\">decision-makers have more confidence in the credibility of their results. </span><span class=\"NormalTextRun SCXW235815615 BCX8\">They include use of standardized protocol templates, pre-registration of study protocols, and moving towards master protocols, with reference to specific tools that are available or in development.</span><span class=\"NormalTextRun SCXW235815615 BCX8\"> </span></span><span class=\"EOP SCXW235815615 BCX8\" data-ccp-props=\"{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}\"> </span></div>\r\n\r\n","sessionCode":"","prereq":"","children":[],"speakers":[{"type":"Moderator","people":[{"fullName":"Richard Willke","lastName":"Willke","city":"Lawrenceville","state":"NJ","country":"USA","bio":"Dick became ISPOR’s first chief science officer in April 2016, following nearly 25 years in the pharmaceutical industry with Pfizer and its legacy companies. In his CSO role at ISPOR, Dick’s responsibilities are to develop, lead, support, and direct strategic initiatives related to research, scientific, and content priorities to accomplish the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. While with Pfizer, his final position was Vice President, Outcomes & Evidence, lead for Cardiovascular /Metabolic, Inflammation & Immunology, the last in a succession of HEOR group lead roles. He received a PhD in economics from Johns Hopkins University in 1982, concentrating in econometrics and labor economics. Prior to joining Pfizer’s legacy company Upjohn in 1991, he was a member of the economics faculty at Ohio State University as well as a senior economist at the American Medical Association Center for Health Policy Research. \r\n\r\nDick has served on the ISPOR Board of Directors (2007-09), was chair of the ISPOR Institutional Council in 2010, and was co-chair of the ISPOR Good Research Practices Task Force on Cost-Effectiveness Analysis in Randomized Clinical Trials in 2003-2005 as well as its 2014-15 reprise to revise and update that Report. He has co-taught many ISPOR short courses on this topic as well as on “Transferability of Cost-Effectiveness Data between Countries.” He was also a member of the Health Outcomes Committee of PhRMA from 1998-2009, having been its chair from 2002-2004. He has served as a co-editor for Value in Health, on the editorial board for Farmeconomia, on AHRQ, NIH, and PCORI project review study sections, and is a member of the Ohio State University Economics Advisory Board.\r\n\r\nPrior to joining industry, Dr Willke served as department director in the Center of Health Policy Research at the American Medical Association and held research and teaching positions at The Ohio State University.\r\n\r\nDr Willke earned a PhD and MA in economics from Johns Hopkins University. He has authored more than 80 scholarly publications that examine the science and methodologies of health economics and outcomes research.","affiliations":"ISPOR","credentials":"PhD","id":"bf04152f-111b-4b8c-9bbe-f414fcee2265","imageUrl":"https://ispor.confex.com/data/image/ispor/intl2019/Person_188820_image_58_0.jpg"}]},{"type":"Speaker","people":[{"fullName":"Adam Aten","lastName":"Aten","city":"Bethesda","state":"MD","country":"USA","bio":"","affiliations":"Duke-Margolis Center for Health Policy","credentials":"MPH, MSc","id":"c25403d5-de6f-47e6-b9ed-91298952c55e","imageUrl":""},{"fullName":"C. Daniel Mullins","lastName":"Mullins","city":"Baltimore","state":"MD","country":"USA","bio":"C. Daniel Mullins, PhD is a professor at the University of Maryland School of Pharmacy. He received his BS in Economics from M.I.T. and his PhD in Economics from Duke University. His research and teaching focus on comparative effectiveness research (CER), patient-centered outcomes research (PCOR), pharmacoeconomics, and health disparities research. He directs the University of Maryland PATient-centered Involvement in Evaluating effectiveNess of TreatmentS (PATIENTS) Program, which received a University of Maryland Baltimore Champion of Excellence Award. He has received funding as a Principal Investigator from the NIH/NIA, NIH/NHLBI, AHRQ, and the Patient-Centered Outcomes Research Institute (PCORI) and was the Shared Resources Core Director for the NIH-sponsored University of Maryland Center for Health Disparities Research, Training, and Outreach.","affiliations":"University of Maryland School of Pharmacy","credentials":"PhD","id":"f1e2593f-b717-488a-80e3-402ad52fb912","imageUrl":"https://ispor.confex.com/data/image/ispor/euro2019/Person_201368_image_194_0.jpg"},{"fullName":"Shirley Wang","lastName":"Wang","city":"Boston","state":"MA","country":"USA","bio":"Dr. Wang is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School. She has led 2 joint task forces between ISPOR and the International Society of Pharmacoepidemiology (ISPE) focused on real-world evidence for healthcare decision-making. Dr. Wang directs the REPEAT Initiative, a non-profit program with projects aimed at improving transparency, reproducibility and robustness of evidence from healthcare databases and co-leads RCT-DUPLICATE, a series of projects designed to inform when and how real-world data analyses can draw causal conclusions to inform regulatory decision-making.","affiliations":"Brigham and Women’s Hospital, Harvard Medical School","credentials":"PhD, MSc","id":"fe15fbc5-defd-4842-9794-028d920d214a","imageUrl":"https://ispor.confex.com/data/image/ispor/intl2022/Person_234317_image_1042_0.jpg"}]}],"sponsorLogo":"","sponsorName":"","scTrack":"","scLevel":"Experienced","relatedPdfs":[{"url":"https://www.ispor.org/docs/default-source/rwes2023/session3slides.pdf?sfvrsn=6555c730_0","title":"Session_3_Slides"}],"confexId":"Session15965","viewingMethods":[],"searchableContent":"","sessionTypes":[{"id":"7e42f173-895f-448e-9964-5e5ca74dfc1b","title":"Issue Panel","urlName":"issue-panel"}],"topics":[{"id":"cd3b717f-305a-455d-b82a-8c3f75a7eb9f","title":"Real World Data & Information Systems","urlName":"real-world-data-information-systems"}],"urlName":"15965","parentUrlName":"rwes2023-3643","parentConfexId":"Symposium3643","shouldShowPdfs":true}],"childCount":1,"posterCategories":[],"programTypes":[{"id":"7c268d2c-e1f1-4b88-8a21-fb677a839ef1","title":"Issue Panel","urlName":"Issue-Panel"}],"confexId":"Symposium3643","viewingMethods":[{"id":"c6f373de-c02f-4f82-b4ce-3943fbc2e424","title":"Live","urlName":"live"}],"urlName":"rwes2023-3643","sponsorLogo":""},{"title":"Session 4","subtitle":"","description":"","startTime":"4:30","startPeriod":"PM","endTime":"5:30","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"39cf830d-fd80-4e20-8945-fc026ffe2810","isPoster":false,"children":[{"title":"Navigating the RWE Landscape - Successes, Struggles, and the Path Forward","id":"aebac599-c147-4fe3-a9d6-11f2ebfccd04","description":"\r\n\t<div><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW66766324 BCX8\"><span class=\"NormalTextRun SCXW66766324 BCX8\">This session will include review of specific cases of RWE use for regulatory or HTA purposes, with consideration of both data and analytic issues</span><span class=\"NormalTextRun SCXW66766324 BCX8\">. </span><span class=\"NormalTextRun SCXW66766324 BCX8\">The discussion will What has worked, what the challenges have been, and what lessons can be drawn for the future.</span></span><span class=\"EOP SCXW66766324 BCX8\" data-ccp-props=\"{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}\"> </span></div>\r\n\r\n","sessionCode":"","prereq":"","children":[],"speakers":[{"type":"Moderator","people":[{"fullName":"Nancy Dreyer","lastName":"Dreyer","city":"Newton","state":"MA","country":"USA","bio":"Nancy Dreyer is Adjunct Professor of Epidemiology at the University of North Carolina at Chapel Hill, a Trustee of Brandeis University and Chief Scientific Officer Emerita at IQVIA Real World Solutions. Well-known for her thought leadership, she is a Fellow of both the International Society of Pharmacoepidemiology and the Drug Information Association. She has helped advance the use of real-world evidence for regulatory purposes, influencing the content of recent guidelines by regulators in the US, Europe, and China, each of which cite one or more of her publications. Her substantial executive and field experience have helped hone her pragmatic views about real-world evidence.","affiliations":"IQVIA Real World Solutions","credentials":"MPH, PhD, FISPE","id":"0af7f870-f2af-456f-b7c5-2cf6d11c866f","imageUrl":"https://ispor.confex.com/data/image/ispor/rwes2023/Person_277304_image_2340_0.jpg"}]},{"type":"Speaker","people":[{"fullName":"Stephen Duffield","lastName":"Duffield","city":"Liverpool","state":"","country":"United Kingdom","bio":"Stephen is an Associate Director at NICE. His role involves the continuing development of NICE’s real-world evidence (RWE) framework, collaboration on RWE demonstration projects, and helping to transform NICE’s use of real-world data across guidance products. He is also involved with upskilling individuals within and externally to the organisation, contributing to training workshops and technical forums. Stephen has a degree in medicine and a PhD in public health. Previously, he worked as a clinical doctor and a guideline developer in NICE Centre for Guidelines","affiliations":"NICE","credentials":"PhD, MD","id":"6f9819c0-b272-44b7-9f28-9f36640a0afb","imageUrl":"https://ispor.confex.com/data/image/ispor/euro2022/Person_264997_image_1658_0.jpg"},{"fullName":"Wim Goettsch","lastName":"Goettsch","city":"Diemen","state":"","country":"Netherlands","bio":"Wim Goettsch, PhD is currently Special Advisor Health Technology Assessment (HTA) at the Dutch National Health Care Institute. Since December 2022, he also has a position as a Professor and Chair on HTA of pharmaceuticals at Utrecht University (NL) where he is leading an H2020 consortium with fifteen partners around Europe, called HTx, new methods for Health Technology Assessment (2019-2024). He was the Director of the EUnetHTA JA3 (2016- 2020) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. He is iinvolved many activities on real world evidence (RWE) such as the GetReal Institute, the ISPE-ISPOR taskforce on RWE transparency, CIOMS WG XII on RWE and the EU stakeholder Advisory Board on DARWIN-EU. He has more than 110 publications in peer-reviewed international journals.","affiliations":"National Health Care Institute (ZIN); Utrecht University, Division of Pharmacoepidemiology and Clinical Pharmacology","credentials":"PhD","id":"ba7dda72-dc12-4dbb-b479-4bbe292f8419","imageUrl":"https://ispor.confex.com/data/image/ispor/euro2021/Person_251879_image_364_0.png"},{"fullName":"Ashley Jaksa","lastName":"Jaksa","city":"Boston","state":"MA","country":"USA","bio":"Ashley Jaksa is Market Access Scientific Strategy Lead at Aetion. She focuses on collaborating with decision-makers to enhance their use of RWE and setting methodological guidance for RWE generation. She also works with Aetion’s biopharma clients on incorporating RWE in their global market access strategy. She has presented her research at numerous international conferences including ISPOR, HTAi, and AMCP, and published her findings in various peer-reviewed publications. She holds a bachelor's degree from the University of Michigan-Ann Arbor and a MPH from Yale University.","affiliations":"Aetion, Inc","credentials":"MPH","id":"3a43e2b5-8f87-4454-8067-a80bf16b205d","imageUrl":"https://ispor.confex.com/data/image/ispor/rwes2023/Person_175089_image_2326_0.jpg"},{"fullName":"Tae Hyun Jung","lastName":"Jung","city":"Silver Spring","state":"MD","country":"USA","bio":"Tae Hyun (Ryan) Jung, Ph.D., is a Senior Statistical Reviewer in the Office of Biostatistics at CDER, FDA. He has comprehensive review experience in phase III reviews including RWE efficacy and phase IV registry/database safety reviews. In addition, he works on clinical research that leverages CMS data and leads RWD projects using machine learning in causal inference and in synthetic data. Tae Hyun joined the FDA in October 2017 after completing his Ph.D. in Biostatistics from Yale University.","affiliations":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration","credentials":"PhD","id":"39bc228a-e4c5-4a93-869c-22cc714ec459","imageUrl":"https://ispor.confex.com/data/image/ispor/intl2023/Person_272087_image_2347_0.jpg"}]}],"sponsorLogo":"","sponsorName":"","scTrack":"","scLevel":"Experienced","relatedPdfs":[{"url":"https://www.ispor.org/docs/default-source/rwes2023/session4slidesv2.pdf?sfvrsn=5987239b_0","title":"Session_4_Slides_v2"}],"confexId":"Session15966","viewingMethods":[],"searchableContent":"","sessionTypes":[{"id":"7e42f173-895f-448e-9964-5e5ca74dfc1b","title":"Issue Panel","urlName":"issue-panel"}],"topics":[{"id":"cd3b717f-305a-455d-b82a-8c3f75a7eb9f","title":"Real World Data & Information Systems","urlName":"real-world-data-information-systems"}],"urlName":"15966","parentUrlName":"rwes2023-3644","parentConfexId":"Symposium3644","shouldShowPdfs":true}],"childCount":1,"posterCategories":[],"programTypes":[{"id":"7c268d2c-e1f1-4b88-8a21-fb677a839ef1","title":"Issue Panel","urlName":"Issue-Panel"}],"confexId":"Symposium3644","viewingMethods":[{"id":"c6f373de-c02f-4f82-b4ce-3943fbc2e424","title":"Live","urlName":"live"}],"urlName":"rwes2023-3644","sponsorLogo":""},{"title":"Closing Remarks","subtitle":"","description":"","startTime":"5:30","startPeriod":"PM","endTime":"5:40","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"cb8a794e-06c1-4164-9c05-3a29ed73d731","isPoster":false,"children":[],"childCount":0,"posterCategories":[],"programTypes":[{"id":"71fc216c-7a21-41c4-8fda-8fd52a67f29d","title":"General Meeting","urlName":"General-Meeting"}],"confexId":"Session15987","viewingMethods":[],"urlName":"rwes2023-15987","sponsorLogo":""},{"title":"Networking Reception","subtitle":"","description":"","startTime":"5:40","startPeriod":"PM","endTime":"6:30","endPeriod":"PM","date":"Sun May 7","longDate":"Sunday, May 7","id":"cae0c709-b1e9-4801-abc9-885ac45a0594","isPoster":false,"children":[],"childCount":0,"posterCategories":[],"programTypes":[{"id":"71fc216c-7a21-41c4-8fda-8fd52a67f29d","title":"General Meeting","urlName":"General-Meeting"}],"confexId":"Session15988","viewingMethods":[],"urlName":"rwes2023-15988","sponsorLogo":""}]; </script> <script> window.mgConfexProgramConfig = window.mgConfexProgramConfig || {}; window.mgConfexProgramConfig.onlyNumberSessionCode = false; window.mgConfexProgramConfig.programType = "symposia"; window.mgConfexProgramConfig.showShortCourseFilters = false; </script> <div id="confex-sessions-v2"> <p><em>* Program subject to change</em></p> </div> <div> <noscript> <h2>Sun May 7</h2> <h3>12:00 PM - 4:00 PM</h3> <h4>Registration Hours</h4> <h3>1:00 PM - 1:10 PM</h3> <h4>Welcome</h4> <h3>1:10 PM - 2:10 PM</h3> <h4>Session 1</h4> <h5>From Data Quality to Qualities</h5> <p><strong>Level: </strong>Experienced</p> <div> <div><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW114023864 BCX8"><span class="NormalTextRun SCXW114023864 BCX8">This session</span><span class="NormalTextRun SCXW114023864 BCX8"> will examine how data quality is described and measured. </span><span class="NormalTextRun SCXW114023864 BCX8">It will include</span><span class="NormalTextRun SCXW114023864 BCX8"> a review</span><span class="NormalTextRun SCXW114023864 BCX8"> and discussion</span><span class="NormalTextRun SCXW114023864 BCX8"> of recent data quality frameworks,</span><span class="NormalTextRun SCXW114023864 BCX8"> </span><span class="NormalTextRun SCXW114023864 BCX8">development</span><span class="NormalTextRun SCXW114023864 BCX8">s in validation</span><span class="NormalTextRun SCXW114023864 BCX8">,</span><span class="NormalTextRun SCXW114023864 BCX8"> and measurement of important aspects of quality. </span><span class="NormalTextRun SCXW114023864 BCX8">It will include presentations from several experts followed by a brief panel discussion and Q&A.</span></span><span class="EOP SCXW114023864 BCX8" data-ccp-props="{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}"> </span></p> <p><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW114023864 BCX8"><span class="NormalTextRun SCXW114023864 BCX8"></span></span></p> <p><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW114023864 BCX8"><span class="NormalTextRun SCXW114023864 BCX8"></span></span></div> </div> <h6>Moderators</h6> <ul> <p><strong>Rachele Hendricks-Sturrup, DHSc, MSc, MA</strong></p> <p>Duke-Margolis Center for Health Policy, Washington, DC, USA</p> </ul> <h6>Speakers</h6> <ul> <p><strong>Andre Araujo, PhD</strong></p> <p>GSK, Kennett Square, PA, USA</p> <div>Andre B. Araujo, PhD is an epidemiologist and is the Head of Real-World Analytics (RWA) at GSK. The RWA team is composed of analysts and data scientists who provide design and analytics to support the generation of high-quality real-world evidence in support of the GSK portfolio. His external engagements include initiatives that focus on best practices in the application of research methods to real-world data in the context of non-interventional study designs.</div> <p><strong>Jaclyn L. Bosco, PhD, MPH</strong></p> <p>IQVIA, Cambridge, MA, USA</p> <div>Dr. Jaclyn Bosco is Vice President and Global Head of Epidemiology at IQVIA. She is responsible for driving real world evidence generation for regulators, clinicians, patients and payers using primary or passive data collection as well as existing data to support the safety and effectiveness of drugs, biologics, and medical devices from early clinical development through the post-approval phase. She sets industry best practices through external thought leadership as an invited speaker and panelist at international congresses and conferences on topics such as generating fit-for-purpose solutions using real-world evidence for regulatory decision-making. </div> <p><strong>Sebastian Schneeweiss, MD, ScD</strong></p> <p>Harvard Medical School; Brigham and Women’s Hospital, Boston, MA, USA</p> </ul> <h3>2:10 PM - 3:10 PM</h3> <h4>Session 2</h4> <h5>Considering Data Qualities in Determining FFP - Can We Converge on an Approach?</h5> <p><strong>Level: </strong>Experienced</p> <div> <div><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW1934789 BCX8"><span class="NormalTextRun SCXW1934789 BCX8">This session </span><span class="NormalTextRun SCXW1934789 BCX8">will be </span><span class="NormalTextRun SCXW1934789 BCX8">focused on the principles and realities of how fit-for-purpose decisions are made based on the needs of the study question and the qualities of the data</span><span class="NormalTextRun SCXW1934789 BCX8">. </span><span class="NormalTextRun SCXW1934789 BCX8">It will be primarily a panel discussion, considering questions such as “</span><span class="NormalTextRun SCXW1934789 BCX8">How does the study question interact with data qualities to determine what’s fit-for-purpose”</span><span class="NormalTextRun SCXW1934789 BCX8">?</span></span><span class="EOP SCXW1934789 BCX8" data-ccp-props="{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}"> </span><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW1934789 BCX8"><span class="NormalTextRun SCXW1934789 BCX8"></span></span></div> </div> <h6>Moderators</h6> <ul> <p><strong>Marc Berger, MD</strong></p> <p>Marc L. Berger, LLC, New York, NY, USA</p> <div>Marc L. Berger, MD, is a semi-retired, part-time consultant and scientific advisor. Until July 2017, he was Vice President, Real World Data and Analytics at Pfizer, Inc. Marc has held senior-level positions in industry including Executive Vice President and Senior Scientist at OptumInsight; Vice President, Global Health Outcomes at Eli Lilly and Company; and Vice President, Outcomes Research and Management at Merck & Co., Inc. He was a temporary employee of CMS from July-December 2022. Marc is an ISPOR Special Advisor for Real World Evidence and a member of the Duke-Margolis Center for Health Policy Real-World Evidence Collaborative. He has written or co-written more than 130 peer-reviewed articles, book chapters, and other publications on a range of topics including health services research, outcomes research, health economics, and health policy. He received the Donabedian Lifetime Achievement Award from ISPOR in 2019.</div> </ul> <h6>Speakers</h6> <ul> <p><strong>John Concato, MD, MS, MPH</strong></p> <p>Food and Drug Administration, Silver Spring, MD, USA</p> <div>John Concato, MD, MS, MPH, is an Associate Director of the Office of Medical Policy, Center for Drug Evaluation and Research, FDA. His responsibilities related to real-world evidence (RWE) include developing internal Agency processes, interacting with stakeholders, coordinating demonstration projects and guidance development, and serving as Chair of the RWE Subcommittee. He joined FDA in 2019 after a career at Yale School of Medicine and the US Department of Veterans Affairs, where he was a clinician, educator, independent investigator, research center director, and Professor of Medicine.</div> <p><strong>Gracy Crane, PhD</strong></p> <p>Roche Products Limited, Welwyn, HRT, United Kingdom</p> <div>Gracy Crane is a cancer biologist by training with a Master in Biomedical Research and a Ph.D. in Cancer Biology. She has also completed post-doctoral training fellowships at Oxford University (UK) and Massachusetts Institute of Technology (USA). She has over 12 years of years of experience in the pharmaceutical industry, in varying roles including medical and scientific affairs, clinical development, health outcomes research and real world data. For the past 5 years, she has worked on leading the real world evidence strategy for molecules within the rare cancer space as part of the global Data Science team at Roche. Currently, she is the RWD policy lead within the Global Regulatory Policy team at Roche. She has authored many publications on this topic and has presented in many international conferences. Gracy is also part of a number of external steering/working groups including the ISPOR RWD transparency Initiative (https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative), the CIOMs working group on RWD/E guidelines, and the Duke Margolis RWE Collaborative. She is also a co-author on the HARPER work: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.5507 This is her LinkedIn Profile: https://www.linkedin.com/in/gracy-crane-374ba120/ </div> <p><strong>Laurie Lambert, PhD</strong></p> <p>Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada</p> <div>Laurie Lambert completed a Master of Public Health in the epidemiology and biostatistics stream at the University of Western Australia. She then received a four-year Australian National Health and Medical Research Training scholarship to pursue her PhD. From 2004 to 2020, Laurie was the scientific coordinator of the Cardiovascular Evaluation Unit at INESSS where the focus was on evaluations of new technologies in the real-world context. In August, 2020 Laurie began a new chapter in her career as Lead of Real World Evidence at CADTH.</div> <p><strong>Daniel Leaver Morales</strong></p> <p>EMA, Amsterdam, Netherlands</p> </ul> <h3>3:10 PM - 3:30 PM</h3> <h4>Break</h4> <h3>3:30 PM - 4:30 PM</h3> <h4>Session 3</h4> <h5>Transparency in RWE: Ensuring Credibility and Confidence</h5> <p><strong>Level: </strong>Experienced</p> <div> <div><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW235815615 BCX8"><span class="NormalTextRun SCXW235815615 BCX8">This session will cover areas of good conduct for RWE studies that help </span><span class="NormalTextRun SCXW235815615 BCX8">decision-makers have more confidence in the credibility of their results. </span><span class="NormalTextRun SCXW235815615 BCX8">They include use of standardized protocol templates, pre-registration of study protocols, and moving towards master protocols, with reference to specific tools that are available or in development.</span><span class="NormalTextRun SCXW235815615 BCX8"> </span></span><span class="EOP SCXW235815615 BCX8" data-ccp-props="{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}"> </span></div> </div> <h6>Moderators</h6> <ul> <p><strong>Richard Willke, PhD</strong></p> <p>ISPOR, Lawrenceville, NJ, USA</p> <div>Dick became ISPOR’s first chief science officer in April 2016, following nearly 25 years in the pharmaceutical industry with Pfizer and its legacy companies. In his CSO role at ISPOR, Dick’s responsibilities are to develop, lead, support, and direct strategic initiatives related to research, scientific, and content priorities to accomplish the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. While with Pfizer, his final position was Vice President, Outcomes & Evidence, lead for Cardiovascular /Metabolic, Inflammation & Immunology, the last in a succession of HEOR group lead roles. He received a PhD in economics from Johns Hopkins University in 1982, concentrating in econometrics and labor economics. Prior to joining Pfizer’s legacy company Upjohn in 1991, he was a member of the economics faculty at Ohio State University as well as a senior economist at the American Medical Association Center for Health Policy Research. Dick has served on the ISPOR Board of Directors (2007-09), was chair of the ISPOR Institutional Council in 2010, and was co-chair of the ISPOR Good Research Practices Task Force on Cost-Effectiveness Analysis in Randomized Clinical Trials in 2003-2005 as well as its 2014-15 reprise to revise and update that Report. He has co-taught many ISPOR short courses on this topic as well as on “Transferability of Cost-Effectiveness Data between Countries.” He was also a member of the Health Outcomes Committee of PhRMA from 1998-2009, having been its chair from 2002-2004. He has served as a co-editor for Value in Health, on the editorial board for Farmeconomia, on AHRQ, NIH, and PCORI project review study sections, and is a member of the Ohio State University Economics Advisory Board. Prior to joining industry, Dr Willke served as department director in the Center of Health Policy Research at the American Medical Association and held research and teaching positions at The Ohio State University. Dr Willke earned a PhD and MA in economics from Johns Hopkins University. He has authored more than 80 scholarly publications that examine the science and methodologies of health economics and outcomes research.</div> </ul> <h6>Speakers</h6> <ul> <p><strong>Adam Aten, MPH, MSc</strong></p> <p>Duke-Margolis Center for Health Policy, Bethesda, MD, USA</p> <p><strong>C. Daniel Mullins, PhD</strong></p> <p>University of Maryland School of Pharmacy, Baltimore, MD, USA</p> <div>C. Daniel Mullins, PhD is a professor at the University of Maryland School of Pharmacy. He received his BS in Economics from M.I.T. and his PhD in Economics from Duke University. His research and teaching focus on comparative effectiveness research (CER), patient-centered outcomes research (PCOR), pharmacoeconomics, and health disparities research. He directs the University of Maryland PATient-centered Involvement in Evaluating effectiveNess of TreatmentS (PATIENTS) Program, which received a University of Maryland Baltimore Champion of Excellence Award. He has received funding as a Principal Investigator from the NIH/NIA, NIH/NHLBI, AHRQ, and the Patient-Centered Outcomes Research Institute (PCORI) and was the Shared Resources Core Director for the NIH-sponsored University of Maryland Center for Health Disparities Research, Training, and Outreach.</div> <p><strong>Shirley Wang, PhD, MSc</strong></p> <p>Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA</p> <div>Dr. Wang is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School. She has led 2 joint task forces between ISPOR and the International Society of Pharmacoepidemiology (ISPE) focused on real-world evidence for healthcare decision-making. Dr. Wang directs the REPEAT Initiative, a non-profit program with projects aimed at improving transparency, reproducibility and robustness of evidence from healthcare databases and co-leads RCT-DUPLICATE, a series of projects designed to inform when and how real-world data analyses can draw causal conclusions to inform regulatory decision-making.</div> </ul> <h3>4:30 PM - 5:30 PM</h3> <h4>Session 4</h4> <h5>Navigating the RWE Landscape - Successes, Struggles, and the Path Forward</h5> <p><strong>Level: </strong>Experienced</p> <div> <div><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW66766324 BCX8"><span class="NormalTextRun SCXW66766324 BCX8">This session will include review of specific cases of RWE use for regulatory or HTA purposes, with consideration of both data and analytic issues</span><span class="NormalTextRun SCXW66766324 BCX8">. </span><span class="NormalTextRun SCXW66766324 BCX8">The discussion will What has worked, what the challenges have been, and what lessons can be drawn for the future.</span></span><span class="EOP SCXW66766324 BCX8" data-ccp-props="{"201341983":0,"335559685":2160,"335559739":160,"335559740":259}"> </span></div> </div> <h6>Moderators</h6> <ul> <p><strong>Nancy Dreyer, MPH, PhD, FISPE</strong></p> <p>IQVIA Real World Solutions, Newton, MA, USA</p> <div>Nancy Dreyer is Adjunct Professor of Epidemiology at the University of North Carolina at Chapel Hill, a Trustee of Brandeis University and Chief Scientific Officer Emerita at IQVIA Real World Solutions. Well-known for her thought leadership, she is a Fellow of both the International Society of Pharmacoepidemiology and the Drug Information Association. She has helped advance the use of real-world evidence for regulatory purposes, influencing the content of recent guidelines by regulators in the US, Europe, and China, each of which cite one or more of her publications. Her substantial executive and field experience have helped hone her pragmatic views about real-world evidence.</div> </ul> <h6>Speakers</h6> <ul> <p><strong>Stephen Duffield, PhD, MD</strong></p> <p>NICE, Liverpool, United Kingdom</p> <div>Stephen is an Associate Director at NICE. His role involves the continuing development of NICE’s real-world evidence (RWE) framework, collaboration on RWE demonstration projects, and helping to transform NICE’s use of real-world data across guidance products. He is also involved with upskilling individuals within and externally to the organisation, contributing to training workshops and technical forums. Stephen has a degree in medicine and a PhD in public health. Previously, he worked as a clinical doctor and a guideline developer in NICE Centre for Guidelines</div> <p><strong>Wim Goettsch, PhD</strong></p> <p>National Health Care Institute (ZIN); Utrecht University, Division of Pharmacoepidemiology and Clinical Pharmacology, Diemen, Netherlands</p> <div>Wim Goettsch, PhD is currently Special Advisor Health Technology Assessment (HTA) at the Dutch National Health Care Institute. Since December 2022, he also has a position as a Professor and Chair on HTA of pharmaceuticals at Utrecht University (NL) where he is leading an H2020 consortium with fifteen partners around Europe, called HTx, new methods for Health Technology Assessment (2019-2024). He was the Director of the EUnetHTA JA3 (2016- 2020) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. He is iinvolved many activities on real world evidence (RWE) such as the GetReal Institute, the ISPE-ISPOR taskforce on RWE transparency, CIOMS WG XII on RWE and the EU stakeholder Advisory Board on DARWIN-EU. He has more than 110 publications in peer-reviewed international journals.</div> <p><strong>Ashley Jaksa, MPH</strong></p> <p>Aetion, Inc, Boston, MA, USA</p> <div>Ashley Jaksa is Market Access Scientific Strategy Lead at Aetion. She focuses on collaborating with decision-makers to enhance their use of RWE and setting methodological guidance for RWE generation. She also works with Aetion’s biopharma clients on incorporating RWE in their global market access strategy. She has presented her research at numerous international conferences including ISPOR, HTAi, and AMCP, and published her findings in various peer-reviewed publications. She holds a bachelor's degree from the University of Michigan-Ann Arbor and a MPH from Yale University.</div> <p><strong>Tae Hyun Jung, PhD</strong></p> <p>Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA</p> <div>Tae Hyun (Ryan) Jung, Ph.D., is a Senior Statistical Reviewer in the Office of Biostatistics at CDER, FDA. He has comprehensive review experience in phase III reviews including RWE efficacy and phase IV registry/database safety reviews. In addition, he works on clinical research that leverages CMS data and leads RWD projects using machine learning in causal inference and in synthetic data. Tae Hyun joined the FDA in October 2017 after completing his Ph.D. in Biostatistics from Yale University.</div> </ul> <h3>5:30 PM - 5:40 PM</h3> <h4>Closing Remarks</h4> <h3>5:40 PM - 6:30 PM</h3> <h4>Networking Reception</h4> </noscript> </div> <script src='/ResourcePackages/ISPOR/modules/confex-sessions-v2/dist/assets/index.js?v=2023-10-26-15:25' type='module'></script> </div> </div> <div class="row section" data-sf-element="Row"> <div id="Main_T8B58AE33015_Col00" class="sf_colsIn col-md-12" data-sf-element="Column 1" data-placeholder-label="Column 1"> <div > <div class="sfContentBlock sf-Long-text" ><hr /></div> </div> </div> </div> </div> </div> <div > <div class="sfContentBlock sf-Long-text" ></div> </div> </main>  <footer class="section__footer py-8"> <div id="footer__links" class="container"> <div class="row"> <div class="col-md-5"> <div > <div class="sfContentBlock sf-Long-text" ><h5>Quick Links</h5><hr /></div> </div> <div> <ul class="footer-nav"> <li class=""> <a href="/about" target="_self">About</a> </li> <li class=""> <a href="/heor-resources/news-top/news/media-center" target="_self">Media Center</a> </li> <li class=""> <a href="/conferences-education/conferences/exhibits-sponsorships" target="_self">Exhibits & Sponsorships</a> </li> <li class=""> <a href="/about/contact-us" target="_self">Contact Us</a> </li> </ul> </div> </div> <div class="col-md-5"> <div > <div class="sfContentBlock sf-Long-text" ><h5>Policies & Legal</h5><hr /></div> </div> <div> <ul class="footer-nav"> <li class=""> <a href="/antitrust-compliance" target="_self">Antitrust Compliance</a> </li> <li class=""> <a href="/code-of-ethics" target="_self">Code of Ethics</a> </li> <li class=""> <a href="/cookie-policy" target="_self">Cookie Policy</a> </li> <li class=""> <a href="/about/our-society/diversity-policy" target="_self">Diversity Policy</a> </li> <li class=""> <a href="/funding-statement" target="_self">Funding Statement</a> </li> <li class=""> <a href="/legal-disclaimer" target="_self">Legal Disclaimer</a> </li> <li class=""> <a href="/privacy-policy" target="_self">Privacy Policy</a> </li> <li class=""> <a href="/terms-and-conditions" target="_self">Terms and Conditions</a> </li> </ul> </div> </div> <div class="col-md-2 mt-9"> <div > <div class="sfContentBlock sf-Long-text" ><p><a class="button secondary" href="/site-map">Site Map</a></p><p><a class="button secondary" href="/media-press">Media/Press</a></p></div> </div></div> </div> </div> <hr> <div class="bkg-white"> <div class="container"> <div id="footer__copyright" class="row"> <div class="col-md-8"> <div > <div class="sfContentBlock sf-Long-text" ><h2>ISPOR–The Professional Society for <br />Health Economics and Outcomes Research</h2></div> </div></div> <div class="col-md-4"> <div class="mt-4" > <div class="sfContentBlock sf-Long-text" ><div class="flex-center"><a class="mr-4" href="mailto:info@ispor.org?subject=Mail%20from%20ISPOR%20web%20site" title="email" data-sf-ec-immutable=""><svg height="30" viewBox="0 0 45 45" width="30"><g fill="none" fill-rule="evenodd"><path d="M22.5,0 C10.0735917,0 0,10.0736016 0,22.5 C0,34.9264055 10.0735945,45 22.5,45 C34.9264125,45 45,34.9264055 45,22.5 C45,10.0735875 34.9264125,0 22.5,0 Z" fill="#27AAE1"></path><path d="M34.8046875,11.25 L10.1953125,11.25 C9.22851562,11.25 8.4375,12.0410156 8.4375,13.0078125 L8.4375,30.5859375 C8.4375,31.5527348 9.22851562,32.34375 10.1953125,32.34375 L34.8046875,32.34375 C35.7714844,32.34375 36.5625,31.5527348 36.5625,30.5859375 L36.5625,13.0078125 C36.5625,12.0410156 35.7714844,11.25 34.8046875,11.25 Z M33.046875,14.765625 L33.046875,16.0290527 L22.5,22.2442383 L11.953125,16.0290527 L11.953125,14.765625 L33.046875,14.765625 Z M11.953125,28.828125 L11.953125,19.0894043 L22.5,25.3045898 L33.046875,19.0894043 L33.046875,28.828125 L11.953125,28.828125 Z" fill="#FFF"></path></g> </svg> </a> <a class="mr-4" href="https://www.linkedin.com/company/ISPORorg" rel="noopener noreferrer" target="_blank" title="LinkedIn" data-sf-ec-immutable=""><svg height="30" viewBox="0 0 45 45" width="30"><path d="M22.5,11 C10.0735917,11 0,21.0736016 0,33.5 C0,45.9264055 10.0735945,56 22.5,56 C34.9264125,56 45,45.9264055 45,33.5 C45,21.0735875 34.9264125,11 22.5,11 Z M17.128125,44.1734375 C17.1074812,44.5062406 16.8421781,44.7715466 16.509375,44.7921889 L12.2906264,44.7921889 C11.9550009,44.7778902 11.6861752,44.509063 11.671875,44.1734375 L11.6718764,29.0703125 C11.6861766,28.7346828 11.9550023,28.4658641 12.2906264,28.4515625 L16.509375,28.4515625 C16.6734703,28.4508313 16.8308297,28.5168125 16.9453125,28.634375 C17.0694844,28.7454266 17.1409781,28.9037422 17.1421875,29.0703125 L17.128125,44.1734375 Z M16.4109375,25.8921875 C15.8651578,26.446025 15.1213078,26.7597594 14.34375,26.7640625 C12.743408,26.7261922 11.4616012,25.4257203 11.4468764,23.825 C11.4420923,23.0497062 11.7575606,22.3068266 12.31875,21.771875 C12.8372442,21.1969859 13.5697809,20.8612437 14.34375,20.84375 C15.1192828,20.8443406 15.8628375,21.1528859 16.4109375,21.7015625 C16.9704844,22.2354031 17.2771594,22.9816578 17.2546875,23.7546875 C17.2931484,24.5428625 16.9848703,25.308425 16.4109375,25.85 L16.4109375,25.8921875 Z M35.49375,44.1734375 C35.4794484,44.509063 35.2106297,44.7778902 34.875,44.7921889 L30.459375,44.7921889 C30.2964891,44.7924673 30.1419141,44.7203295 30.0375,44.5953111 C29.9264063,44.4776572 29.8658391,44.3211627 29.86875,44.1593778 L29.86875,34.90625 C29.921175,34.2686281 29.7631125,33.6313859 29.41875,33.0921875 C28.9789031,32.6534797 28.3620375,32.4409531 27.7453125,32.515625 C26.8913672,32.4371422 26.0571516,32.8037656 25.5375,33.4859375 C25.111575,34.2174969 24.9155859,35.0602625 24.975,35.9046875 L24.975,44.0890611 C24.9606984,44.4246852 24.6918797,44.6935067 24.35625,44.7078111 L20.1375,44.7078111 C19.8018703,44.6935095 19.5330516,44.424688 19.51875,44.0890611 L19.51875,29.0703125 C19.5330516,28.7346828 19.8018703,28.4658641 20.1375,28.4515625 L24.35625,28.4515625 C24.5309766,28.4368391 24.7025672,28.5044375 24.8203125,28.634375 C24.9670969,28.9253141 25.0257516,29.2527734 24.9890625,29.5765625 C26.1486141,28.5496625 27.6601359,28.0105625 29.2078125,28.071875 C30.8519578,28.0057531 32.4647438,28.5350375 33.75,29.5625 C34.9414734,30.7216437 35.5592391,32.3484219 35.4375,34.00625 L35.49375,44.1734375 Z" fill="#27AAE1" fill-rule="evenodd" transform="translate(0 -11)"></path></svg> </a> <a class="mr-4" href="http://www.facebook.com/pages/International-Society-for-Pharmacoeconomics-and-Outcomes-Research-ISPOR/100220853389399" rel="noopener noreferrer" target="_blank" title="FaceBook" data-sf-ec-immutable=""><svg height="30" viewBox="0 0 45 45" width="30" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="M44.972 22.499c0 12.424-10.068 22.498-22.485 22.498C10.067 44.997 0 34.923 0 22.5 0 10.072 10.068 0 22.487 0 34.904 0 44.972 10.072 44.972 22.5" fill="#27AAE1"></path><path d="M19.482 33.749h4.67V22.506h3.15l.409-3.971h-3.559v-2.336c0-.876.58-1.082.99-1.082h2.511v-3.855l-3.459-.013c-3.84 0-4.712 2.875-4.712 4.715v2.571H17.26v3.971h2.22V33.75z" fill="#FFF"></path></g> </svg></a> <a class="mr-4" href="https://twitter.com/ispororg" rel="noopener noreferrer" target="_blank" title="Twitter" data-sf-ec-immutable=""><svg height="30" viewBox="0 0 46 45" width="30" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="M45.677 22.498c0 12.425-10.067 22.499-22.484 22.499-12.42 0-22.487-10.074-22.487-22.498C.706 10.072 10.774 0 23.193 0 35.61 0 45.677 10.072 45.677 22.498" fill="#27AAE1"></path><path d="M36.281 11.671a11.551 11.551 0 0 1-3.663 1.403 5.752 5.752 0 0 0-4.208-1.824 5.769 5.769 0 0 0-5.766 5.771c0 .453.051.892.148 1.315a16.367 16.367 0 0 1-11.885-6.03 5.747 5.747 0 0 0-.781 2.903 5.769 5.769 0 0 0 2.566 4.8 5.736 5.736 0 0 1-2.612-.72v.072a5.775 5.775 0 0 0 4.626 5.658 5.772 5.772 0 0 1-2.605.1 5.775 5.775 0 0 0 5.387 4.006 11.568 11.568 0 0 1-7.163 2.471c-.464 0-.924-.028-1.374-.081a16.315 16.315 0 0 0 8.839 2.591c10.607 0 16.405-8.79 16.405-16.417 0-.248-.003-.499-.014-.747a11.698 11.698 0 0 0 2.876-2.985 11.506 11.506 0 0 1-3.312.908 5.787 5.787 0 0 0 2.536-3.194" fill="#FFF"></path></g> </svg></a> <a class="mr-4" href="http://www.youtube.com/user/ISPORorg" rel="noopener noreferrer" target="_blank" title="YouTube" data-sf-ec-immutable=""><svg height="30" viewBox="0 0 45 45" width="30"><path d="M18.6609375,30.1640625 L28.2515625,22.5 L18.6609375,14.8359375 L18.6609375,30.1640625 Z M22.5,0 C10.0735917,0 0,10.0736016 0,22.5 C0,34.9264055 10.0735945,45 22.5,45 C34.9264125,45 45,34.9264055 45,22.5 C45,10.0735875 34.9264125,0 22.5,0 Z M37.8421875,28.2515625 C37.8344531,31.424857 35.2639125,33.9954005 32.090625,34.0031278 L12.909375,34.003125 C9.73608047,33.9953948 7.16554125,31.424857 7.15781109,28.2515625 L7.1578125,16.7484375 C7.16554266,13.57515 9.73608187,11.0046094 12.909375,10.996875 L32.090625,10.996875 C35.2639125,11.0046094 37.8344531,13.57515 37.8421875,16.7484375 L37.8421875,28.2515625 Z" fill="#27AAE1" fill-rule="evenodd"></path></svg></a> <a href="https://www.instagram.com/ISPORorg/" rel="noopener noreferrer" target="_blank" title="Instagram" data-sf-ec-immutable=""><svg height="30" viewBox="0 0 46 45" width="30" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="M45.133 22.498c0 12.425-10.068 22.499-22.484 22.499C10.229 44.997.16 34.923.16 22.499.161 10.072 10.23 0 22.65 0c12.416 0 22.484 10.072 22.484 22.498" fill="#27AAE1"></path><path d="M22.647 9c-3.664 0-4.123.016-5.562.081-1.436.066-2.417.294-3.275.628a6.613 6.613 0 0 0-2.39 1.557 6.618 6.618 0 0 0-1.556 2.391c-.334.859-.562 1.84-.627 3.277-.066 1.44-.081 1.9-.081 5.566s.015 4.126.08 5.566c.066 1.437.294 2.418.628 3.277.345.888.806 1.64 1.556 2.391a6.613 6.613 0 0 0 2.39 1.557c.858.334 1.839.562 3.275.628 1.439.065 1.898.081 5.562.081 3.664 0 4.124-.016 5.563-.081 1.436-.066 2.416-.294 3.274-.628a6.613 6.613 0 0 0 2.39-1.557 6.618 6.618 0 0 0 1.556-2.391c.334-.859.562-1.84.627-3.277.066-1.44.082-1.9.082-5.566s-.016-4.126-.082-5.566c-.065-1.437-.293-2.418-.627-3.277a6.618 6.618 0 0 0-1.556-2.391 6.613 6.613 0 0 0-2.39-1.557c-.858-.334-1.838-.562-3.274-.628C26.77 9.016 26.31 9 22.647 9zm0 2.432c3.602 0 4.03.014 5.452.08 1.315.06 2.03.28 2.505.464a4.18 4.18 0 0 1 1.551 1.01c.472.472.765.922 1.01 1.552.184.476.404 1.19.464 2.507.065 1.423.079 1.85.079 5.455s-.014 4.032-.079 5.455c-.06 1.316-.28 2.031-.465 2.507a4.182 4.182 0 0 1-1.009 1.552 4.18 4.18 0 0 1-1.551 1.01c-.475.185-1.19.405-2.505.465-1.423.065-1.85.079-5.452.079-3.603 0-4.03-.014-5.452-.08-1.315-.06-2.03-.28-2.505-.464a4.18 4.18 0 0 1-1.551-1.01 4.183 4.183 0 0 1-1.01-1.552c-.184-.476-.404-1.19-.464-2.507-.065-1.423-.079-1.85-.079-5.455s.014-4.032.08-5.455c.06-1.316.279-2.031.464-2.507.244-.63.537-1.08 1.009-1.552a4.18 4.18 0 0 1 1.551-1.01c.476-.185 1.19-.405 2.505-.465 1.423-.065 1.85-.079 5.452-.079zm0 4.136A6.93 6.93 0 0 0 15.72 22.5a6.93 6.93 0 0 0 6.928 6.932 6.93 6.93 0 0 0 6.928-6.932 6.93 6.93 0 0 0-6.928-6.932zm0 11.432a4.499 4.499 0 0 1-4.497-4.5c0-2.485 2.013-4.5 4.497-4.5a4.499 4.499 0 0 1 4.497 4.5c0 2.485-2.013 4.5-4.497 4.5zm8.82-11.706a1.62 1.62 0 1 1-3.238 0 1.62 1.62 0 0 1 3.239 0z" fill="#FFF"></path></g> </svg></a> </div></div> </div> <div > <div class="sfContentBlock sf-Long-text" ><p class="m-0 text--sm">Copyright © <span class="copy-year">2018</span> <a href="/home">ISPOR</a>. All rights reserved. </p><p class="is-accent-lighter my-0 text--xsm">International Society for Pharmacoeconomics and Outcomes Research, Inc</p><p class="m-0 text--sm">Website Design & Development by <a href="https://www.matrixgroup.net/" target="_blank">Matrix Group</a></p></div> </div></div> </div> </div> </div> </footer>  <script src='/ResourcePackages/ISPOR/assets/dist/js/site.js?v=2024-11-14-15:00'></script> </body> </html>